Journal of International Oncology ›› 2021, Vol. 48 ›› Issue (10): 627-630.doi: 10.3760/cma.j.cn371439-20201230-00123
• Reviews • Previous Articles Next Articles
Niu Wenjuan1, Duan Wenjie1, Su Yating1, Wei Fang2()
Received:
2020-12-30
Revised:
2021-04-27
Online:
2021-10-08
Published:
2021-11-24
Contact:
Wei Fang
E-mail:2yuanweifang@163.com
Supported by:
Niu Wenjuan, Duan Wenjie, Su Yating, Wei Fang. Consideration on the new stage of cervical cancer revised by the International Federation of Obstetrics and Gynecology in 2018[J]. Journal of International Oncology, 2021, 48(10): 627-630.
[1] |
Zhang X, Lv Z, Xu X, et al. Comparison of adenocarcinoma and adenosquamous carcinoma prognoses in Chinese patients with FIGO stageⅠB-ⅡA cervical cancer following radical surgery[J]. BMC Cancer, 2020, 20(1):664. DOI: 10.1186/s12885-020-07148-x.
doi: 10.1186/s12885-020-07148-x |
[2] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI: 10.3322/caac.21492.
doi: 10.3322/caac.21492 |
[3] |
中华人民共和国国家卫生健康委员会. 宫颈癌诊疗规范(2018年版)[J]. 肿瘤综合治疗电子杂志, 2020, 6(3):33-43. DOI: 10.12151/JMCM.2020.03-06.
doi: 10.12151/JMCM.2020.03-06 |
[4] |
Dos Reis R, Andrade CEMC, Frumovitz M, et al. Radical hysterectomy and age: outcomes comparison based on a minimally invasive vs an open approach[J]. J Minim Invasive Gynecol, 2018, 25(7):1224-1230. DOI: 10.1016/j.jmig.2018.03.002.
doi: 10.1016/j.jmig.2018.03.002 |
[5] |
Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer[J]. N Engl J Med, 2018, 379(20):1895-1904. DOI: 10.1056/NEJMoa1806395.
doi: 10.1056/NEJMoa1806395 |
[6] |
许燕萍, 王志启, 梁旭东, 等. 局部晚期子宫颈癌患者腹腔镜与开腹手术的预后比较[J]. 中华妇产科杂志, 2020, 55(9):609-616. DOI: 10.3760/cma.j.cn112141-20200727-00612.
doi: 10.3760/cma.j.cn112141-20200727-00612 |
[7] |
Levine MD, Brown J, Crane EK, et al. Outcomes of minimally invasive versus open radical hysterectomy for early stage cervical cancer incorporating 2018 FIGO staging[J]. J Minim Invasive Gynecol, 2020, 28(4):824-828. DOI: 10.1016/j.jmig.2020.07.021.
doi: 10.1016/j.jmig.2020.07.021 |
[8] |
Saleh M, Virarkar M, Javadi S, et al. Cervical cancer: 2018 revised International Federation of Gynecology and Obstetrics staging system and the role of imaging[J]. AJR Am J Roentgenol, 2020, 214(5):1182-1195. DOI: 10.2214/AJR.19.21819.
doi: 10.2214/AJR.19.21819 |
[9] |
杨东, 张洪文, 刘辉, 等. CT、MRI及正电子发射体层成像CT在宫颈癌诊断中的应用[J]. 国际肿瘤学杂志, 2014, 41(3):220-223. DOI: 10.3760/cma.j.issn.1673-422X.2014.03.019.
doi: 10.3760/cma.j.issn.1673-422X.2014.03.019 |
[10] |
Balcacer P, Shergill A, Litkouhi B. MRI of cervical cancer with a surgical perspective: staging, prognostic implications and pitfalls[J]. Abdom Radiol (NY), 2019, 44(7):2557-2571. DOI: 10.1007/s00261-019-01984-7.
doi: 10.1007/s00261-019-01984-7 |
[11] |
Merz J, Bossart M, Bamberg F, et al. Revised FIGO staging for cervical cancer-a new role for MRI[J]. Rofo, 2020, 192(10):937-944. DOI: 10.1055/a-1198-5729.
doi: 10.1055/a-1198-5729 |
[12] |
Salvo G, Odetto D, Pareja R, et al. Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: a review of gaps and questions that remain[J]. Int J Gynecol Cancer, 2020, 30(6):873-878. DOI: 10.1136/ijgc-2020-001257.
doi: 10.1136/ijgc-2020-001257 |
[13] |
Salib MY, Russell JHB, Stewart VR, et al. 2018 FIGO staging classification for cervical cancer: added benefits of imaging[J]. Radiographics, 2020, 40(6):1807-1822. DOI: 10.1148/rg.2020200013.
doi: 10.1148/rg.2020200013 |
[14] |
Jung W, Park KR, Lee KJ, et al. Value of imaging study in predicting pelvic lymph node metastases of uterine cervical cancer[J]. Radiat Oncol J, 2017, 35(4):340-348. DOI: 10.3857/roj.2017.00206.
doi: 10.3857/roj.2017.00206 |
[15] |
Zhang X, Dong Y, Song Q, et al. The role of multiparametric magnetic resonance imaging in the study of primary tumor and pelvic lymph node metastasis in stage ⅠB1-ⅡA1 cervical cancer[J]. J Comput Assist Tomogr, 2020, 44(5):750-758. DOI: 10.1097/RCT.0000000000001084.
doi: 10.1097/RCT.0000000000001084 |
[16] |
Mansoori B, Khatri G, Rivera-Colón G, et al. Multimodality imaging of uterine cervical malignancies[J]. AJR Am J Roentgenol, 2020, 215(2):292-304. DOI: 10.2214/AJR.19.21941.
doi: 10.2214/AJR.19.21941 |
[17] |
Haldorsen IS, Lura N, Blaakór J, et al. What is the role of imaging at primary diagnostic work-up in uterine cervical cancer?[J]. Curr Oncol Rep, 2019, 21(9):77. DOI: 10.1007/s11912-019-0824-0.
doi: 10.1007/s11912-019-0824-0 pmid: 31359169 |
[18] |
Zyla RE, Gien LT, Vicus D, et al. The prognostic role of horizontal and circumferential tumor extent in cervical cancer: implications for the 2019 FIGO staging system[J]. Gynecol Oncol, 2020, 158(2):266-272. DOI: 10.1016/j.ygyno.2020.05.016.
doi: 10.1016/j.ygyno.2020.05.016 |
[19] |
Matsuo K, Machida H, Mandelbaum RS, et al. Validation of the 2018 FIGO cervical cancer staging system[J]. Gynecol Oncol, 2019, 152(1):87-93. DOI: 10.1016/j.ygyno.2018.10.026.
doi: S0090-8258(18)31309-X pmid: 30389105 |
[20] | 钟云. FIGO宫颈癌新分期系统的临床探讨[D]. 郑州: 郑州大学, 2020. |
[21] |
Ayhan A, Aslan K, Bulut AN, et al. Is the revised 2018 FIGO staging system for cervical cancer more prognostic than the 2009 FIGO staging system for women previously staged as ⅠB disease?[J]. Eur J Obstet Gynecol Reprod Biol, 2019, 240:209-214.DOI: 10.1016/j.ejogrb.2019.07.002.
doi: S0301-2115(19)30329-X pmid: 31325847 |
[22] |
Fan Y, Wang MY, Mu Y, et al. Ovarian metastasis in women with cervical carcinoma in stages ⅠA to ⅡB: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2020, 99(31):e21146. DOI: 10.1097/MD.0000000000021146.
doi: 10.1097/MD.0000000000021146 |
[23] |
Nanthamongkolkul K, Hanprasertpong J. Predictive factors of pelvic lymph node metastasis in early-stage cervical cancer[J]. Oncol Res Treat, 2018, 41(4):194-198. DOI: 10.1159/000485840.
doi: 10.1159/000485840 pmid: 29562222 |
[24] |
Pedone Anchora L, Carbone V, Gallotta V, et al. Should the number of metastatic pelvic lymph nodes be integrated into the 2018 Figo staging classification of early stage cervical cancer?[J]. Cancers (Basel), 2020, 12(6):1552. DOI: 10.3390/cancers12061552.
doi: 10.3390/cancers12061552 |
[25] |
Li A, Wang L, Jiang Q, et al. Risk stratification based on metastatic pelvic lymph node status in stage ⅢC1p cervical cancer[J]. Cancer Manag Res, 2020, 12:6431-6439. DOI: 10.2147/CMAR.S253522.
doi: 10.2147/CMAR.S253522 |
[26] |
Li C, Liu W, Cheng Y. Prognostic significance of metastatic lymph node ratio in squamous cell carcinoma of the cervix[J]. Onco Targets Ther, 2016, 9:3791-3797. DOI: 10.2147/OTT.S97702.
doi: 10.2147/OTT.S97702 |
[27] |
Aslan K, Meydanli MM, Oz M, et al. The prognostic value of lymph node ratio in stage ⅢC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy[J]. J Gynecol Oncol, 2020, 31(1):e1. DOI: 10.3802/jgo.2020.31.e1.
doi: 10.3802/jgo.2020.31.e1 |
[28] |
Cibula D, McCluggage WG. Sentinel lymph node (SLN) concept in cervical cancer: current limitations and unanswered questions[J]. Gynecol Oncol, 2019, 152(1):202-207. DOI: 10.1016/j.ygyno.2018.10.007.
doi: S0090-8258(18)31286-1 pmid: 30318103 |
[29] |
徐红, 张静. 美国国立综合癌症网络《2020年宫颈癌临床实践指南》病理内容更新解读[J]. 中华病理学杂志, 2021, 50(1):9-13. DOI: 10.3760/cma.j.cn112151-20200712-00548.
doi: 10.3760/cma.j.cn112151-20200712-00548 |
[30] | 刘成伟. 验证2018 FIGO宫颈癌新分期系统[D]. 南昌: 南昌大学, 2019. |
[31] |
Liu X, Wang J, Hu K, et al. Validation of the 2018 FIGO staging system of cervical cancer for stage Ⅲpatients with a cohort from China[J]. Cancer Manag Res, 2020, 12:1405-1410. DOI: 10.2147/CMAR.S239624.
doi: 10.2147/CMAR.S239624 |
[32] |
Liu X, Wang W, Hu K, et al. A risk stratification for patients with cervical cancer in stage ⅢC1 of the 2018 FIGO staging system[J]. Sci Rep, 2020, 10(1):362. DOI: 10.1038/s41598-019-57202-3.
doi: 10.1038/s41598-019-57202-3 |
[33] |
Grigsby PW, Massad LS, Mutch DG, et al. FIGO 2018 staging criteria for cervical cancer: impact on stage migration and survival[J]. Gynecol Oncol, 2020, 157(3):639-643. DOI: 10.1016/j.ygyno.2020.03.027.
doi: S0090-8258(20)30252-3 pmid: 32248993 |
[1] | Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291. |
[2] | Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483. |
[3] | Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376. |
[4] | Ma Xueyan, Lu Lili, Sun Pengfei. Advances in the immune microenvironment in cervical cancer [J]. Journal of International Oncology, 2023, 50(1): 47-50. |
[5] | Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou. Advances in immunotherapy for recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 517-520. |
[6] | Shi Yingxia, Hu Lijun, Yu Jingping. Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 568-571. |
[7] | Peng Chen, Xie Yintong, Zhang Xin, Xie Peng. Research progress of maintenance therapy for cervical cancer [J]. Journal of International Oncology, 2022, 49(7): 430-435. |
[8] | Xiong Chan, Yan Ying, Xie Xiaodong, Meng Fanjie, Yu Huiying. Study on the biological characteristics of polyploid cervical cancer HeLa cells induced by radiation [J]. Journal of International Oncology, 2022, 49(5): 263-269. |
[9] | Yuan Chenyang, Zhou Juying. Research progress on prognostic factors of cervical cancer [J]. Journal of International Oncology, 2022, 49(5): 307-313. |
[10] | Yuan Chenyang, Zhou Juying, Du Xiao, Ji Huan, Zhao Tianyi. Comparison of 2018 and 2009 FIGO staging system of cervical cancer and analysis of prognostic factors [J]. Journal of International Oncology, 2022, 49(3): 151-163. |
[11] | Wang Yue, Wu Qiong, Xu Yuan, Gong Wei, Xu Xiaoting. Screening and treatment progression of elderly cervical cancer [J]. Journal of International Oncology, 2022, 49(12): 754-758. |
[12] | Ma Xiuzhen, Lu Yan, Zhao Bingbing, Qiu Hongcong, Xu Xun, Wei Min. Effects of total flavonoids from Baeckea frutescens on the migration, invasion and apoptosis of cervical cancer SiHa cells [J]. Journal of International Oncology, 2021, 48(4): 206-211. |
[13] | Yu Mingyue, Chen Zhengzheng, Zhao Xuxu, Ren Pingping, Zhang Ying, Ge Li, Zhu Meiling, Zhao Weidong. Factors related to postoperative adjuvant therapy of locally advanced cervical cancer and building of a nomogram prediction model [J]. Journal of International Oncology, 2021, 48(1): 35-40. |
[14] | Ding Xuchao, Cao Lili. Common active targeting nano drug delivery systems for cervical cancer [J]. Journal of International Oncology, 2021, 48(1): 61-64. |
[15] | Shu Hang, Xu Zhonghua, Zhu Haochen, Yang Yahui, Lyu Yin. Research progress of radiosensitivity in cervical cancer [J]. Journal of International Oncology, 2020, 47(8): 496-500. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||